Epstein-Barr virus latent membrane protein 1 peptide-major histocompatibility complex (EBV LMP1 pMHC)

The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) peptide-major histocompatibility complex (pMHC) is a critical therapeutic target for EBV-associated malignancies. LMP1 is the primary oncogene of EBV, acting as a functional mimic of the CD40 receptor to drive constitutive signaling through NF-κB, PI3K/Akt, and MAPK pathways, which promotes cell survival and proliferation (Young et al., 2016, Nature Reviews Cancer). Because LMP1 is a multi-pass transmembrane protein with very small extracellular loops, it is difficult to target with conventional monoclonal antibodies. However, the protein is processed intracellularly into short peptides, such as the immunodominant YLLEMLWRL epitope, which are then presented on the cell surface by MHC Class I molecules, most commonly HLA-A*02:01 (Tang et al., 2022, Frontiers in Immunology). This pMHC complex serves as a highly specific molecular signature for EBV-transformed cells in diseases like nasopharyngeal carcinoma and Hodgkin lymphoma. Current immunotherapeutic strategies, including TCR-engineered T cells and TCR-like antibodies, are designed to recognize this specific peptide-MHC configuration to selectively eliminate malignant cells while sparing healthy tissue (He et al., 2015, Journal of Virology). This approach allows for the targeting of an intracellular viral oncogene by exploiting the natural antigen presentation machinery of the host cell.

Other names

LMP1-HLA complexLMP1 peptide-MHC Class I complexEBV LMP1-HLA-A*02:01 complexLMP1 pMHC

Binding of engineered T-cell receptors (TCRs) or TCR-like antibodies to the specific viral peptide (e.g., YLLEMLWRL) presented by MHC Class I molecules on the cell surface, which triggers T-cell mediated cytotoxicity and apoptosis of the EBV-infected or transformed cell.